Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.

Wang C, Lu X, Zhou Z, Wang J, Hui Z, Liang J, Feng Q, Chen D, Xiao Z, Lv J, Wang X, Wang X, Zhang T, Deng L, Wang W, Xiao J, Li J, Bi N, Wang L.

J Cancer. 2019 May 12;10(9):1985-1990. doi: 10.7150/jca.30131. eCollection 2019.

2.

Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.

Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2.

PMID:
27034176
3.

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.

Wang W, Song Z, Zhang Y.

Arch Med Sci. 2018 Oct;14(6):1298-1307. doi: 10.5114/aoms.2018.78939. Epub 2018 Oct 23.

4.

Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.

Du XJ, Pan SM, Lai SZ, Xu XN, Deng ML, Wang XH, Yao DC, Wu SX.

Front Oncol. 2018 Dec 12;8:603. doi: 10.3389/fonc.2018.00603. eCollection 2018.

5.

Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.

Liu Y, Deng L, Zhou X, Gong Y, Xu Y, Zhou L, Wan J, Zou B, Wang Y, Zhu J, Ding Z, Peng F, Huang M, Ren L, Lautenschlaeger T, Kong FS, Lu Y.

Oncotarget. 2017 Nov 30;8(67):111309-111317. doi: 10.18632/oncotarget.22785. eCollection 2017 Dec 19.

7.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.

J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.

PMID:
28113019
8.

Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.

Wang C, Lu X, Lyu Z, Bi N, Wang L.

Lung Cancer. 2018 Aug;122:94-99. doi: 10.1016/j.lungcan.2018.05.014. Epub 2018 May 18.

PMID:
30032853
9.

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H.

Oncotarget. 2017 Feb 21;8(8):13304-13311. doi: 10.18632/oncotarget.14515.

10.

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.

Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):604-613. doi: 10.1016/j.ijrobp.2019.02.051. Epub 2019 Mar 6.

PMID:
30851347
11.

EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

Soon YY, Leong CN, Koh WY, Tham IW.

Radiother Oncol. 2015 Feb;114(2):167-72. doi: 10.1016/j.radonc.2014.12.011. Epub 2015 Jan 9. Review.

PMID:
25583566
12.
13.

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Chen Y, Yang J, Li X, Hao D, Wu X, Yang Y, He C, Wang W, Wang J.

Cancer Sci. 2016 Dec;107(12):1800-1805. doi: 10.1111/cas.13079. Epub 2016 Nov 25.

14.

Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer.

Wang H, Yu X, Fan Y, Jiang Y.

Onco Targets Ther. 2018 Apr 13;11:2149-2155. doi: 10.2147/OTT.S156570. eCollection 2018.

15.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.

Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.

16.

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Li C, Guo J, Zhao L, Hu F, Nie W, Wang H, Zheng X, Shen Y, Gu P, Zhang Y, Zhang X.

Cancer Manag Res. 2019 Apr 23;11:3433-3443. doi: 10.2147/CMAR.S196881. eCollection 2019.

17.

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):322-9. doi: 10.1016/j.ijrobp.2014.02.022. Epub 2014 Mar 25.

18.

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.

Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.

J Neurooncol. 2014 Nov;120(2):423-30. doi: 10.1007/s11060-014-1570-7. Epub 2014 Aug 7.

19.

Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.

Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D, Kong R, Chen Z, Sun J.

Clin Transl Oncol. 2018 Mar;20(3):366-373. doi: 10.1007/s12094-017-1723-1. Epub 2017 Aug 3.

PMID:
28776311
20.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL.

Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.

PMID:
28734822

Supplemental Content

Support Center